Document:

Revolving Unsecured Promissory Note

 Exhibit 10.1 
 REVOLVING UNSECURED PROMISSORY NOTE 
  

			
	$1,000,000	  	 Tampa, Florida
 October 5, 2011

 FOR VALUE RECEIVED, ORAGENICS, INC., a Florida corporation located at 3000 Bayport Drive, Suite 685, Tampa, Florida 32607
(“Borrower”), hereby promises to pay to the order of KOSKI FAMILY LIMITED PARTNERSHIP, a Texas limited partnership having a mailing address of 3525 Turtle Creek Boulevard, Unit 19-B, Dallas, Texas 75219 (“Lender”),
the sum of One Million Dollars ($1,000,000), together with interest thereon as provided herein. All sums are payable by personal delivery or by mail to Lender at the address listed above, or at such other address as Lender may designate to Borrower.
This note is provided pursuant to the Revolving Credit Agreement dated July 30, 2010 as amended by the First Amendment dated January 24, 2011, the Second Amendment dated February 4, 2011 and the Third Amendment dated June 29,
2011, by and between Lender and Borrower. 
  

	1.	Interest. The unpaid principal balance under this Revolving Unsecured Promissory Note (“Promissory Note”) shall bear interest from the date
hereof at an annual rate equal to the London Interbank Offered Rate (LIBOR) plus six percent (6%) (the “Applicable Rate”). The Applicable Rate shall be adjusted quarterly on the first day of each calendar quarter while any
principal balance hereunder remains unpaid, based on the LIBOR in effect on the business day immediately preceding such adjustment date. 

  

	2.	Payment of Principal and Interest. The principal of this Promissory Note, together with all accrued interest thereon, shall be due and payable on July 30,
2012. Any portion of the principal of this Promissory Note may be prepaid, together with the accrued interest with respect to such principal payment, prior to maturity, without penalty. Any payment made under this Promissory Note shall be applied
first to accrued interest and then to principal. Payment of principal and interest shall be made in such coin or currency of the United States of America that, at the time of payment, constitutes legal tender for the payment of public and private
debt. 

  

	3.	Events of Default. The occurrence of any of the following events shall constitute an “Event of Default”: 

(a) the failure of Borrower to pay all or any portion of the principal and interest due and payable under this Promissory Note and such
failure continues for five (5) business days after the Lender notifies Borrower in writing of such failure; 
 (b) the
filing against Borrower of an involuntary petition or other pleading seeking the entry of a decree or order for relief under the United States Bankruptcy Code or any similar federal or state insolvency or other similar law ordering: (i) the
liquidation of Borrower, (ii) a reorganization of Borrower or the business and affairs of Borrower, or (iii) the appointment of a receiver, liquidator, assignee, custodian, trustee or similar official for Borrower or the property of
Borrower, and the failure to have such petition or other pleading denied or dismissed within thirty (30) days from the date of filing; 

 (c) the commencement by Borrower of a voluntary case under the United States Bankruptcy Code
or any similar federal or state insolvency or other similar law, (ii) the consent by Borrower to the appointment or taking possession by a receiver, liquidator, assignee, trustee, custodian or similar official for Borrower or any of the
property of Borrower, or (iii) the making by Borrower of an assignment for the benefit of creditors. 
 (d) the breach of
any term of any of the Loan Documents as defined in that Revolving Credit Agreement of July 30, 2010 by and between Borrower and Lender. 
  

	4.	Rights and Remedies Upon Default. Upon the occurrence of an Event of Default, the principal and all accrued but unpaid interest due under this Promissory Note
shall, at the option of Lender, become immediately due and payable and may be collected forthwith without notice to Borrower, regardless of the stipulated date of maturity and, in that event, Borrower promises to pay, in addition to the unpaid
principal and interest hereunder, all costs, including reasonable attorneys’ fees, paralegals’ fees and expenses for any primary, appellate, bankruptcy and post-judgment proceedings, that Lender may incur or be put to in the collection of
such amounts. Any overdue payment of principal or interest due under this Promissory Note shall bear interest from the due date at twelve percent (12%) per annum. 

 

	5.	Waiver. Borrower hereby waives protest, demand, presentment and notice of dishonor, notice of the maturity, nonpayment, and all requirements necessary to hold it
liable as the maker of this Promissory Note, and agrees that this Promissory Note may be extended in whole or in part without limit as to the number of such extensions or the period or periods thereof, and without notice to it and without affecting
its liability hereunder. Failure to accelerate the debt in the event of any default hereunder, or other indulgence granted from time to time, shall not be construed as a novation of this Promissory Note or a waiver of the right of Lender to
thereafter insist upon strict compliance with the terms of this Promissory Note without previous written notice of such intention being given to Borrower. 

  

	6.	Compliance With Usury Laws. All agreements between Borrower and Lender are hereby expressly limited so that in no event shall the amount paid or agreed to be
paid to Lender for the use, forbearance, or detention of the money loaned under this Promissory Note exceed the maximum amount permissible under the laws of the State of Florida. If, at the time of any interest payment, the payment amount due under
this Promissory Note is in excess of the legal limit, the obligation shall be reduced to the legal limit. If Borrower should ever receive, as interest, an amount that exceeds the highest lawful rate, the amount that would be excessive as interest
shall be applied to the reduction of the principal amount owing under this Promissory Note, and not to the payment of interest. 

  

	7.	Waiver of Jury Trial. BORROWER HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED
HEREON, OR ARISING OUT OF, UNDER OR IN CONJUNCTION WITH, THIS PROMISSORY NOTE AND ANY OTHER AGREEMENT CONTEMPLATED TO BE EXECUTED IN CONJUNCTION HEREWITH, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN) OR ACTIONS
OF EITHER PARTY. 

	8.	Choice of Law; Venue. The laws of the State of Florida, excluding its choice of law provisions if such laws would result in the application of laws other than
the laws of the State of Florida, shall govern any disputes with respect to this Promissory Note, the validity of this Promissory Note, the construction of its terms, and the interpretation of the rights and duties of Borrower and Lender hereunder.
The forum selected for any proceeding or suit related to a dispute between Borrower and Lender related to this Promissory Note shall be in a federal or state court of competent jurisdiction located in Hillsborough County, Florida. Borrower consents
to said courts’ personal jurisdiction over it and waives any defense, whether asserted by motion or pleading, that Hillsborough County, Florida is an improper or inconvenient venue. 

 

	9.	Notice. Any notice, demand or other communication to Borrower that is permitted or required hereunder shall be given in writing, and shall be deemed to have been
duly delivered (i) when delivered by personal delivery, (ii) three (3) days after being deposited with the United States Postal Service for mailing by first class mail, postage prepaid, certified mail, with return receipt requested
(regardless of whether the return receipt is subsequently received), or (iii) one business day after being deposited with a nationally recognized courier service for overnight delivery; and in each case addressed by Lender to Borrower at the
address for Borrower first listed above, or to such other address as Borrower may notify Lender in writing in conformity with the provisions of this Section. 

 

	10.	Documentary Stamp Taxes. Borrower shall pay all documentary stamp taxes due on the obligation evidenced by this Promissory Note. 

 

	11.	Assignment. Lender may assign all or any portion of this Promissory Note and Lender’s rights thereunder. 

 

	12.	Binding Effect. This Promissory Note shall be binding upon Borrower and its successors and assigns, and shall inure to the benefit of Lender and its successors
and assigns. 

  

	13.	Computation of Time. Whenever the last day for payment of any amount due hereunder shall fall upon Saturday, Sunday or any public or legal holiday, whether
federal or of the State of Florida, Borrower shall have until 5:00 p.m. on the next succeeding regular business day to make such payment. 

 IN WITNESS WHEREOF, Borrower has executed this Promissory Note on the date indicated below. 
  

			
	ORAGENICS, INC.
		
	By:	 	 /s/ Brian Bohunicky

	Name:	 	 Brian Bohunicky

	Title:	 	 Chief Financial Officer

	Date:	 	 October 5, 2011Exhibit 10.1

 Exhibit 10.1 
 Confidential treatment requested under 17 C.F.R. §§ 200.80(b)(4) and 230.406. The confidential portions of this exhibit have been omitted and are marked accordingly. The confidential portions
have been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request. 

PATENT LICENSE AGREEMENT 

This Agreement is between the Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of
Texas, whose address is 201 West 7th Street, Austin, Texas 78701, and Axogen Corporation., a corporation having a principal place of business located at 2153 SE Hawthorne Road, Gainesville, FL, 32641 (“Licensee”). 

TABLE OF CONTENTS 
  

					
	1. RECITALS	  	 	3	  
		
	2. DEFINITIONS	  	 	3	  
		
	3. GRANT	  	 	5	  
		
	   3.1   EXCLUSIVE GRANT
	  	 	5	  
	   3.2   AFFILIATES
	  	 	5	  
	   3.3   SUBLICENSING
	  	 	5	  
		
	4. FEES AND ROYALTIES	  	 	6	  
		
	   4.1   RUNNING ROYALTY
	  	 	6	  
	   4.2   PAST PATENT EXPENSES
	  	 	7	  
	   4.3   SUBLICENSEE FEES AND
ROYALITES
	  	 	7	  
	   4.4   MILESTONE FEES AND
MILESTONES
	  	 	8	  
	   4.5   ACTIVELY COMMERCIALIZE
	  	 	8	  
		
	5. REPORTS AND PLANS	  	 	8	  
		
	   5.1   ROYALTY REPORTS
	  	 	8	  
	   5.2   PROGRESS REPORT AND COMMERCIALIZATION
PLAN
	  	 	8	  
		
	6. PAYMENT, RECORDS, AND AUDITS	  	 	9	  
		
	   6.1   PAYMENTS
	  	 	9	  
	   6.2   SALES OUTSIDE THE U.S.
	  	 	9	  
	   6.3   LATE PAYMENTS
	  	 	9	  
	   6.4   RECORDS
	  	 	9	  
	   6.5   AUDITING
	  	 	10	  
		
	7. FUTURE PATENT EXPENSES AND PROSECUTION	  	 	10	  
		
	   7.1   FUTURE PATENT EXPENSES
	  	 	10	  
	   7.2   DEFAULT IN PAYMENT
	  	 	10	  
	   7.3   PATENT ATTORNEY
	  	 	10	  
		
	8. TERM AND TERMINATION	  	 	11	  
		
	   8.1   TERMINATION AT END OF
TERM
	  	 	11	  
	   8.2   TERMINATION BY LICENSEE
	  	 	11	  
	   8.3   TERMINATION BY BOARD
	  	 	12	  
	   8.4   OTHER CONDITIONS OF
TERMINATION
	  	 	12	  
	   8.5   SURVIVAL
	  	 	12	  
		
	9. CONFIDENTIALITY	  	 	13	  
		
	   9.1   PROTECTION AND MARKING
	  	 	13	  
	   9.2   NON-DISCLOSURE
	  	 	13	  

					
	   9.3   NON-USE
	  	 	13	  
	   9.4   COPIES
	  	 	13	  
	   9.5   CONTINUING OBLIGATIONS
	  	 	13	  
	   9.6   DEGREE OF CARE AND
SURVIVAL OF OBLIGATIONS
	  	 	14	  
	   9.7   PUBLICATION BY UNIVERSITY
	  	 	14	  
	   9.8   COPYRIGHT NOTICE
	  	 	14	  
		
	10. INFRINGEMENT AND LITIGATION	  	 	14	  
		
	 10.1   NOTIFICATION
	  	 	14	  
	 10.2   LICENSEE PROSECUTION RIGHTS
	  	 	14	  
	 10.3   BOARD’S RIGHT TO
INTERVENE
	  	 	14	  
	 10.4   BOARD’S PROSECUTION RIGHTS
	  	 	15	  
	 10.5   COOPERATION BETWEEN BOARD, UNIVERSITY,
AND LICENSEE
	  	 	15	  
		
	11. EXPORT COMPLIANCE	  	 	15	  
		
	12. REPRESENTATIONS AND DISCLAIMERS	  	 	16	  
		
	 12.1   BOARD REPRESENTATION
	  	 	16	  
	 12.2   GOVERNMENT RIGHTS
	  	 	16	  
	 12.3   BOARD DISCLAIMERS
	  	 	16	  
	 12.4   LICENSEE REPRESENTATIONS
	  	 	16	  
		
	13. LIMIT OF LIABILITY	  	 	16	  
		
	14. INDEMNIFICATION	  	 	17	  
		
	15. INSURANCE	  	 	17	  
		
	 15.1   INSURANCE REQUIREMENTS
	  	 	17	  
	 15.2   EVIDENCE OF INSURANCE AND NOTICE
OF CHANGES
	  	 	17	  
	 15.3   CONTINUING INSURANCE OBLIGATIONS
	  	 	17	  
	 15.4   ADDITIONAL INSURANCE
	  	 	17	  
		
	16. ASSIGNMENT	  	 	17	  
		
	17. GOVERNMENTAL MARKINGS	  	 	18	  
		
	 17.1   PATENT MARKING
	  	 	18	  
	 17.2   GOVERNMENTAL APPROVALS AND MARKETING
OF LICENSED PRODUCTS
	  	 	18	  
	 17.3   FOREIGN REGISTRATION
	  	 	18	  
		
	18. USE OF NAME	  	 	18	  
		
	 18.1   BY LICENSEE
	  	 	18	  
	 18.2   BY BOARD OR UNIVERSITY
	  	 	18	  
		
	19. NOTICES	  	 	18	  
		
	20. GENERAL PROVISIONS	  	 	19	  
		
	 20.1   BINDING EFFECT
	  	 	19	  
	 20.2   CONSTRUCTION OF AGREEMENT
	  	 	19	  
	 20.3   COUNTERPARTS
	  	 	19	  
	 20.4   ENFORCEMENT
	  	 	19	  
	 20.5   COMPLIANCE WITH LAWS
	  	 	19	  
	 20.6   E-MAILS
	  	 	19	  
	 20.7   GOVERNING LAW
	  	 	19	  
	 20.8   MODIFICATION
	  	 	19	  
	 20.9   SEVERABILITY
	  	 	20	  
	 20.10 SURVIVAL
	  	 	20	  
	 20.11 THIRD PARTY BENEFICIARIES
	  	 	20	  

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 2 of 30

					
	 20.12 Waiver
	  	 	20	  

 Exhibit A: Licensed Patents 
 Exhibit B: Royalty Report 
 Exhibit C: Progress Report and Commercialization Plan

 Exhibit D: Capitalization Table 
  

	1.	Recitals 

 A. WHEREAS, Board owns rights
to the Licensed Subject Matter that was developed at The University of Texas at Austin (“University”), a component institution of System; and 
 B. WHEREAS, Licensee desires to secure the right and license to use, develop, manufacture, market, and commercialize the Licensed Subject Matter; and 

C. WHEREAS, Board has determined that such use, development and commercialization of the Licensed Subject Matter is in the public’s best interest
and is consistent with Board’s educational and research missions and goals; and 
 D. WHEREAS, Board desires to have the Licensed Subject
Matter developed and used for the benefit of Licensee, Inventor, Board and the public as outlined in Board’s Intellectual Property Policy. 

NOW, THEREFORE, in consideration of the mutual covenants and premises herein contained, the parties agree as follows: 

 

	2.	Definitions 

  

	2.1	“Actively Commercialize” means having programs for: (i) research and development for Licensed Product(s) and for obtaining any required regulatory
approvals for said Licensed Product(s), and (ii) in due course, for manufacturing, marketing and Sales of Licensed Product(s), all in a Licensed Field in the Licensed Territory, and all in accordance with Licensee’s Progress Report and
Commercialization Plan. 

  

	2.2	“Affiliate” means any Entity more than 50% owned by Licensee, any Entity which owns more than 50% of Licensee, or any Entity that is more than 50%
owned by an Entity that owns more than 50% of Licensee. 

  

	2.3	“Board’s Intellectual Property Policy” means The University of Texas Regents’ Rule and Regulations, Part Two, Chapter XII.

  

	2.4	“Confidential Information” means all information that is of a confidential and proprietary nature to University or to Licensee and its Affiliates, as
further discussed in Section 9 (“Confidentiality”), including information disclosed during any discussions or negotiations pertaining to this Agreement, or information that is disclosed pursuant to this Agreement.

  

	2.5	“Effective Date” means July 19, 2005. 

  

	2.6	“Entity” means a corporation, an association, a joint venture, a partnership, a trust, a business, an institution, an individual, a government or
political subdivision thereof, including an agency, or any other organization that can exercise independent legal standing. 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 3 of 30

	2.7	“Fair Market Value” means the cash consideration which Licensee or its Sublicensee would realize from an unaffiliated, unrelated buyer in an arm’s
length Sale of an identical item sold in the same quantity, under the same terms, and at the same time and place. 

  

	2.8	“Indemnitees” will have the meaning set forth in Section 15 (“Indemnification”). 

 

	2.9	“Insolvent” means being unable to meet one’s debt obligations to another Entity as such debt obligations become due and not being able to provide
reasonable financial assurances of becoming able to meet such obligations. 

  

	2.10	“Inventor/Principal Investigator” means Dr. Christine Schmidt. 

 

	2.11	“Valid and Issued Claim” means a valid claim that is included in a patent issued and approved from the relevant patent authority in the relevant territory and
is included in Licensed Patents. 

  

	2.12	“Licensed Field” means all applications relating to nerve regeneration and repair. 

 

	2.13	“Licensed Patents” means those United States patent applications and patents listed in Exhibit A and any corresponding foreign patent applications and
patents, and any improvements, divisionals, continuations, reissues, and reexaminations thereof to the extent that the claims are directed to the subject matter within the Licensed Field. 

 

	2.14	“Licensed Product(s)” means any product(s) whose manufacture, use or sale is covered by any Valid and Issued claim of the Licensed Patents; or
product(s) which are made using a process or machine covered by a Valid and Issued claim of the Licensed Patents; or product(s) made, at least in part, using Valid or Issued Claims of the Licensed Patents. Licensed Product(s) will also include any
service rendered through the use of a product, process or machine covered by any Valid and Issued claim of the Licensed Patent. 

  

	2.15	“Licensed Subject Matter” means the Licensed Patents and Licensed Technology within the Licensed Field. 

 

	2.16	“Licensed Technology” means technical data and information created by Inventor at University until two years after the Effective Date that are not
included in the Licensed Patents but which are necessary for practicing the invention covered by Licensed Patents within the Licensed Field. 

  

	2.17	“Licensed Territory” means worldwide, subject to the then-current applicable article, item, service, technology, and technical data-specific
requirements of the U.S. export laws and regulations. 

  

	2.18	“Net Sales” means the gross revenue, monies or cash equivalent, received by Licensee, Affiliates or Sublicensees from the Sale of Licensed Products
less the following items directly attributable to the Sale of such Licensed Products by Licensee, Affiliates or Sublicensees, and specifically identified on the invoice, included in the gross revenues, and borne by the seller: (a) discounts,
rebates, or returns sales, use, customs, duties or other similar taxes and handling charges and allowances; (b) sales and use taxes actually paid by the seller;; .and (c) outbound transportation expenses. 

 

	2.19	“Progress Report and Commercialization Plan” means the progress report and commercialization plan due from Licensee to University in the form set forth
in Exhibit B as referenced in section 6.2. 

  

	2.20	“Royalty Report” means the report due from Licensee to University in the form set forth in Exhibit C. 

 

	2.21	 “Sale or Sold” means any bona fide transaction for which consideration is received or expected for the sale, use, lease, transfer, or
other disposition of Licensed Product(s). A Sale will be deemed completed at 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 4 of 30

	 	
the time Licensee or its Affiliate or its Sublicensee invoices, ships, or receives payment for such Licensed Product(s), whichever occurs first. 

 

	2.22	“Sublicensee” means any party other than an Affiliate that enters into an agreement or arrangement with Licensee or receives a license grant from
Licensee under the Licensed Patents to manufacture, have manufactured, offer for sale, sell, lease, and/or import the Licensed Products. 

  

	2.23	“Sublicensee Breach” is defined in Section 3.3(d) 

  

	2.24	“Sublicensee Fees” are defined in Section 4.5 

  

	2.25	“Term of this Agreement” will commence on the Effective Date and continue until the date of expiration of the last to expire of the Licensed Patents.

  

	3.	Grant 

  

	3.1	Exclusive Grant 

  

	 	a.	Board grants to Licensee a royalty-bearing, exclusive license under Licensed Patents to manufacture, have manufactured, offer for sale, sell, lease, and/or import
Licensed Products in the Licensed Field in the Licensed Territory. This grant is subject to the payment by Licensee to University of all consideration required under this Agreement, to any rights of the Government of the United States as set forth
in Section 12.2 (“Government Rights”), and is further subject to rights retained by Board and University to: 

  

	 	i.	publish the general scientific findings from research conducted in whole or in part at University or otherwise within the System related to Licensed Subject Matter
subject to the terms of Section 9 (“Confidentiality”); and 

  

	 	ii.	use the Licensed Subject Matter for research, teaching and other educationally-related purposes without any royalty obligations for such use. 

 

	 	b.	Board grants to Licensee a royalty-bearing, exclusive license under the Licensed Technology to manufacture, have manufactured, offer for sale, sell, lease, and/or
import Licensed Products in the Licensed Field in the Licensed Territory. 

  

	3.2	Affiliates 

 Licensee may
extend the license granted herein to any Affiliate if the Affiliate consents in writing to be bound by this Agreement to the same extent as Licensee; provided, however, that any fee or other consideration paid to Licensee in consideration of such
extension will be subject to the provisions of Section 4.4(“Assignment”). Other agreements or arrangements with Affiliates relating to Licensed Subject Matter which result in the Sale of Licensed Product(s) will be subject to the
royalty payment and other applicable payment provisions of this Agreement. 
  

	3.3	Sublicensing 

 Licensee
will have the right to grant sublicenses to third parties under Section 3.1 (Grant), subject to the following conditions: 
  

	 	a.	In each such sublicense, the Sublicensee will be permitted to grant further sublicenses, but only on the condition that any such sublicense will be subject to the terms
and conditions of the license granted to Licensee under this Agreement, including payments to University of Sublicensee Fees based upon consideration paid by any further sublicensee for any such further sublicense. 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 5 of 30

	 	b.	Licensee will forward to University, within thirty (30) days following its execution, a fully executed, complete and accurate copy written in the English language
of each sublicense granted under this Agreement. University’s receipt of such sublicense will not constitute a waiver of any of Board’s rights or Licensee’s obligations under this Agreement. 

 

	 	c.	If Licensee becomes Insolvent, Board’s proportionate share of all payments then or thereafter due and owing to Licensee from its Sublicensees for the sublicense of
the Licensed Patents will, upon notice from Board or University to any such Sublicensee, become payable directly to University for the account of Licensee; provided however, that University will remit to Licensee the amount by which such payments
exceed the amounts owed by Licensee to Board. 

  

	 	d	Notwithstanding any such sublicense, Licensee will remain primarily liable to Board for all of Licensee’s duties and obligations contained in this Agreement, and
any act or omission of a Sublicensee that would be a breach of this Agreement if performed by Licensee will be deemed to be a breach by Licensee of this Agreement. Each sublicense will contain a right of termination by Licensee in the event that the
Sublicensee breaches the payment obligations affecting Board or any other material terms and conditions of the sublicense that would constitute a breach of the terms and conditions of this Agreement if such acts were performed by Licensee (a
“Sublicensee Breach”). In the event of a Sublicensee Breach, and if after a reasonable opportunity to cure as provided in any such Sublicensee, such Sublicensee fails to cure such Sublicensee Breach, then Licensee will terminate the
sublicense unless Board agrees in writing that such sublicense need not be terminated. Such Sublicensee Breach and termination of a Sublicensee’s sublicense will not affect the term of Licensee’s license hereunder or the sublicense of any
non-breaching Sublicensee. 

  

	 	e	Upon termination of this Agreement for any reason, all sublicenses will, at Board’s option, be (a) assigned to and assumed by Board, or (b) terminated.

  

	4.	Fees and Royalties 

 In consideration of
rights granted by Board to Licensee under this Agreement, Licensee will pay University the following fees and royalties. Each payment will reference UTAUS Agreement No. PM0505001 and will be made separately from any other fees or payments due under
this Agreement and sent to the address in Section 6.1 (“Payments”). 
  

	4.1	Running Royalty 

  

	4.2	After the first of; two years after the Effective Date; or the issuance of a Valid and Issued Claim in the relevant territory, Licensee will pay a running royalty equal
to [**]% of Net Sales for Licensed Product(s) Sold by Licensee or Affiliate that are covered by valid claims of the Licensed Patents [**] or divisionals, continuations, reissues, and reexaminations thereof. 

Royalty payments will be made simultaneously with the delivery of the quarterly Royalty Reports required under Section 5.1
(“Royalty Reports”). 
 Notwithstanding the royalty rates set forth in Sections 4.1 (“Running Royalty”) and,
if Licensee, Sublicensee, or Affiliate is required to pay royalties to third parties in connection with the Sale of Licensed Product(s) either under license agreements for other technologies which Licensee, in Licensee’s, 

 

	**	Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment
Request. 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 6 of 30

 
Sublicensee’s, or Affiliate’s reasonable judgment, determines are desirable to be incorporated in such Licensed Product(s), or under license agreements with third parties that are joint
owners of patent applications or patents within the Licensed Patents, and the total royalties to be paid by Licensee to University and third parties would exceed [**]% on Sales of Licensed Product(s) (the “Applicable Royalty Stack Cap”)
the amount to be paid under Section 4.1 (“Running Royalty”) will be calculated as follows: 
 The royalty payments
to Board will be reduced by an amount proportionate to the amount by which the total royalties exceeds the Royalty Stack Cap. Specifically: 
  

			
		  	R2 = R1 × (Applicable Royalty Stack Cap / T)
		
	 where
	  	R1 is the earned royalties due the Board hereunder;
		  	R2 is the adjusted reduced royalty rate due hereunder;
		  	T is the total royalty due to all licensors; and
		  	Applicable Royalty Stack Cap: [**]%.

 For example, if one additional licenses are needed from one additional third party, and this other royalty
rate is [**]% and the earned royalties also due the Board are [**]%, then the value of T is [**]%, and the royalty rate under this Agreement, as adjusted will be [**] or [**]%. However, the percentage due the Board will never be reduced to less than
[**]%. 
  

	4.3	Past Patent Expenses 

Licensee will pay $[**] as reimbursement for past expenses in filing and prosecuting patent applications included in Licensed Patents due
and payable no later than October 15, 2005 . Licensee will pay future patent expenses as set forth in Section 7 (“Future Patent Expenses and Prosecution”). 

 

	4.4	Sublicensee Fees and Royalites 

 Within thirty (30) days after receipt of payment by Licensee, Licensee will promptly pay University the following percent of any sublicense fee, sublicense milestone payment, royalties and other
consideration, excluding equity in investments in Licensee in which no license or sublicense rights are conveyed, payable.by each Sublicensee to Licensee or an Affiliate in consideration for Sublicense of the Licensed Patents, excluding funds or
materials paid to Licensee exclusively for research and development related to Licensed Product(s) and, provided further, that the rights granted to sublicensee are limited to research and development work (so long as the funding does not reflect a
premium of more than [**]% over Licensee’s actual costs to perform said work) and do not permit the Sale of the Licensed Product(s) (collectively called “Sublicensee Fees”): 

 

	 	a.	Before the first Sale of Licensee’s nerve graft product, [**] percent ([**]%) of Sublicense Fees for any Sublicense executed. 

 

	 	b.	After the first Sale of Licensee’s nerve graft product, [**] percent ([**]%) of Sublicense Fees for any Sublicense executed. 

Any non-cash consideration, not including equity investments in Licensee, received by Licensee or an Affiliate from such Sublicensees will
be valued at its Fair Market Value as of the date of receipt by Licensee or an Affiliate. 
  

	**	Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment
Request. 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 7 of 30

	4.5	Milestone Fees and Milestones 

 Licensee will meet development milestones for Licensed Product(s) as outlined below in accordance with the following schedule: 

 

	 	a.	As of April 1, 2006, Licensee, with Inventor’s input, will submit at least one grant application for the further development of Licensed Products. Licensee
and Inventor will equitably split any grant monies based on the work scope. University’s share of grant monies will be payable within 30 days of receipt by Licensee. 

 

	 	b.	Within 24 months of the realization of revenue using Licensed Subject Matter, Licensee will pay to University a milestone fee of [**] ($[**]). 

 

	 	c.	Within 30 days of receiving its first Phase II award for an SBIR or STTR grant involving the Licensed Technology, Licensee will pay to the University a milestone fee of
$15,000. 

  

	 	d.	Within 30 days of receiving a Valid Claim of a Licensed Patent that protects the ongoing commercial sale of a Licensed Product, or within 30 days of commercial sale of
a Licensed Product protected by a Valid Claim of the Licensed Patent, whichever comes first, Licensee will pay the University a milestone of $[**]. 

 Each required payment will be paid to University by the date listed above. 
  

	4.6	Actively Commercialize 

Licensee shall actively commercialize the Licensed Subject Matter during the Term of this Agreement. 

 

	5.	Reports and Plans 

  

	5.1	Royalty Reports 

 Within
30 days after March 31, June 30, September 30, and December 31, beginning immediately after the Effective Date, Licensee will deliver to University a true and accurate written Royalty Report, certified by the chief
financial officer or similar officer of Licensee even if no payments are due Board, giving the particulars of the business conducted by Licensee, Affiliate and its Sublicensee(s), if any exist, during the preceding 3 (three) calendar months as are
pertinent to calculating payments hereunder. This report will be in the form set forth in Exhibit C (Form of Royalty Report). University may change the required Form of Royalty Report upon ninety (90) days notice to Licensee. Simultaneously
with the delivery of each report, Licensee will pay to University the amount due, if any, for the period of each Royalty Report. Licensee’s failure to submit a Royalty Report in the required form will constitute a breach of this Agreement.
Licensee will continue to deliver Royalty Reports to University after the termination or expiration of this Agreement until such time as all Licensed Product(s) permitted to be Sold after termination have been Sold or destroyed. 

 

	5.2	Progress Report and Commercialization Plan 

 On or before each anniversary of the Effective Date, whether or not a first Sale or offer for Sale has occurred, Licensee will deliver to University a true and accurate written Progress Report and
Commercialization Plan, certified by the chief operating officer or similar officer of Licensee, as to Licensee’s (and any Sublicensee’s) efforts and accomplishments during preceding year in Commercializing the Licensed Subject Matter in
the Licensed Territory and Licensee’s (and any Affiliate’s and/or Sublicensee’s) plans for the upcoming year for commercializing the Licensed Subject Matter. The 

 

	**	Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment
Request. 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 8 of 30

 
Progress Report and Commercialization Plan will be in the form set forth in Exhibit B. University may change the required Form of Progress Report and Commercialization Plan upon ninety
(90) days notice to Licensee. Licensee’s failure to submit a Progress Report and Commercialization Plan in the required form will constitute a breach of this Agreement. 

The Progress Report and Commercialization Plan will be sent to: 

 

			
		  	Office of Technology Commercialization
		  	The University of Texas at Austin
		  	 3925 West Braker Lane, Suite 1.9A

		  	MCC Building, Mail Code: R3500
		  	Austin, Texas 78759
		  	 Attn: Contract Manager

  

	6.	Payment, Records, and Audits 

  

	6.1	Payments 

 All dollar
amounts referred to in this Agreement are expressed in United States dollars without deductions for taxes, assessments, fees, or charges of any kind. Each payment will reference UTA US Agreement No. PM0505001 and will be made separately from any
other fees or payments due under this Agreement. All payments to University will be made in United States dollars by check payable to “The University of Texas at Austin” and sent to: 

 

	
	 Office of Technology Commercialization

	 The University of Texas at Austin

	 3925 West Braker Lane, Suite 1.9A

	 MCC Building, Mail Code: R3500

	 Austin, Texas 78759

	 Attn: Accounts Receivable

  

	6.2	Sales Outside the U.S. 

The remittance of royalties payable on Sales made outside the United States will be payable to University in United States Dollar
equivalents; provided, however if any currency conversion shall be required in connection with the payment of royalties hereunder, such conversion shall be made by using the exchange rates used by Licensee in calculating Licensee’s own revenues
for financial reporting purposes in accordance with Generally Accepted Accounting Principles. If the transfer of or the conversion into the United States Dollar equivalents of any such remittance in any such instance is not lawful or possible, the
payment of such part of the royalties as is necessary will be made by the deposit thereof, in the currency of the country where the Sale was made on which the royalty was based to the credit and account of University or its nominee in any commercial
bank or trust company of University’s choice located in that country, prompt written notice of which will be given by Licensee to University. 
  

	6.3	Late Payments 

 Amounts
that are not paid when due will accrue interest from the due date until paid, at a rate equal to one percent (1.0%) per month (or the maximum allowed by law, if less). 

 

	6.4	Records 

 Licensee will
maintain, and cause its Sublicensees and Affiliates to maintain complete and accurate books and records that enable all royalties payable under this Agreement to be verified. The records for each calendar quarter will be maintained for three
(3) years after the submission of each report under Section 5.1 (“Royalty Reports”). 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 9 of 30

	6.5	Auditing 

 Upon reasonable
prior notice to Licensee, Affiliates, or Sublicensees, University or its representatives or its appointed accountants will have access to such books and records relating to Net Sales as necessary to conduct a review or audit of Net Sales and verify
all royalty reports submitted and royalty payments. Such access will be available to University upon not less than ten (10) days written notice to Licensee, Affiliates, or Sublicensees, not more than once each calendar year of the Term, during
normal business hours, and once a year for three years after the expiration or termination of this Agreement. Whenever these books and records are audited by an independent certified public accountant, University will, within (thirty) 30 days of the
conclusion of such audit, provide to Licensee a written statement, certified by said auditor, setting forth the calculation of royalties due to University over the time period audited as determined from the audit of paid books and records. If such
audit indicates that Licensee, Affiliates, or Sublicensees has underpaid royalties by more than 10%, Licensee will pay the reasonable costs and expenses incurred by University and its representatives and accountants, if any, in connection with the
review or audit and Licensee will immediately remit such underpaid royalties and Sublicensee Fees and any accrued interest to University. 
  

	7.	Future Patent Expenses and Prosecution 

  

	7.1	Future Patent Expenses 

Licensee will pay future expenses incurred after Effective Date for filing, prosecuting, enforcing, and maintaining the Licensed Patents.

  

	7.2	Default in Payment 

 In
the event that Licensee fails to pay any patent expenses required under this Agreement, and said default is not cured within sixty (60) days after receipt of notification that such expenses are due, then University may pursue its remedies as
specified in Section 9.3. Alternatively, University may require and request that Licensee establish with a bank approved by University, an irrevocable and confirmed letter of credit (not restricted, unless otherwise agreed upon) in the amount
of US $[**] in favor of University available immediately to secure the payment of patent expenses due under this Agreement. University may draw upon such letter of credit upon presentation of the letter notifying Licensee of patent expenses due and
payable and a statement from University of Licensee’s failure to pay; and Licensee will cause the bank to restore the letter of credit to the US $[**] level. In the event that Licensee does not establish (or restore) such letter of credit
within thirty (30) days of University’s request, then Board may immediately terminate this Agreement. 
  

	7.3	Patent Attorney 

University will work closely with Licensee to develop a suitable strategy for the prosecution and maintenance of all Licensed Patents;
provided that Board will maintain final authority in all decisions regarding the patent attorney who prosecutes and maintains the Licensed Patents. University will confer with Licensee regarding the choice of patent counsel and will identify to
Licensee the patent attorney selected to prosecute the Licensed Patents. It is intended that Licensee will interact directly with the selected patent counsel in all phases of patent prosecution: preparation, office action responses, filing
strategies for continuation or divisional applications, and 
  

	**	Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment
Request. 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 10 of 30

 
other related activities. University will request that copies of all documents prepared by the selected patent counsel be provided to Licensee for review and comment prior to filing to the extent
practicable under the circumstances. Licensee will be billed and will pay all documented costs and fees and other charges incident to the preparation, prosecution, and maintenance of the Licensed Patents within sixty (60) days of receipt of
invoice. All patent applications and patents will be in the name of Board, owned by Board and included as part of the Licensed Patents licensed pursuant to this Agreement. 
 If Licensee has a strong need to use a patent attorney other than the patent attorney selected by University, Licensee and University will cooperate to endeavor to select a patent attorney who is mutually
approved by both Licensee and University. Any such mutually selected patent attorney will be required to keep both Licensee and Board, as co-clients, equally informed and involved as to all material information, material communications with
governmental patent offices, material issues and decisions, and related matters applicable to prosecuting the patent applications for the Licensed Patents and for maintaining the Licensed Patents in good standing. Decisions for prosecuting the
patent applications will be made so as to obtain as broad of patent protection as is reasonable and practical under the circumstances. Board will request that copies of all documents prepared by the selected patent attorney be provided to Licensee
for review and comment prior to filing to the extent practicable under the circumstances. 
 Licensee will be billed in
accordance with 7.1 above and will pay all documented costs and fees and other charges incident to the preparation, prosecution, and maintenance of the Licensed Patents, within thirty (30) days after receipt of invoice from the selected patent
attorney. Licensee will promptly notify Board of its plans to file, revise or drop any patent application or claim which may adversely affect the Licensed Patents or the rights or royalties of Board in the Licensed Subject Matter under this
Agreement. Licensee and the selected patent attorney shall not change any inventorship designations, and shall not drop or reduce any claim in a pending patent application which may adversely affect the Licensed Patents or royalties of Board in the
Licensed Subject Matter without written University approval. 
  

	8.	Term and Termination 

  

	8.1	Termination at End of Term 

This Agreement, unless sooner terminated as provided herein, will terminate at the end of the Term of this Agreement as defined in
Section 2 (“Definitions”). 
  

	8.2	Termination by Licensee 

Licensee, at its option, may terminate this Agreement at any time by doing all of the following: 

 

	 	a.	By ceasing to develop, make, have made, use and sell and/or import any Licensed Product(s); 

 

	 	b.	By giving sixty days (60) days prior written notice to Board of Licensee’s termination. Licensee agrees that Board and University may immediately begin
negotiations with other potential licensees upon delivery of such notice to Board and that all other obligations of Licensee under this Agreement will continue until the date of termination; and 

 

	 	c.	By tendering payment of all accrued royalties and other payments due to Board as of the date of the termination. 

Licensee, at its option, may terminate this Agreement upon written notice to Board if Board breaches this Agreement and does not cure such
breach within sixty (60) days after the delivery of written notice from Licensee. 
  

	8.3	Termination by Board 

Board, at its option, may immediately terminate this Agreement, or any part of Licensed Subject Matter, or any part of Licensed Field, or
any part of Licensed Territory, upon delivery of written notice to Licensee of Board’s intent to terminate, if any of the following occur: 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 11 of 30

	 	a.	Licensee fails to Actively Commercialize Licensed Subject Matter during the Term of this Agreement; or 

 

	 	b.	Licensee has not had a Sale of any Licensed Product(s) within three (3) years after the Effective Date; or 

 

	 	c.	Licensee has had time to meet and has not met and satisfied any one of the specified milestones in Section 4.6; or 

 

	 	d.	Licensee becomes more than sixty (60) days in arrears in any payments, fees or other expenses due under to this Agreement; or 

 

	 	e.	Licensee is in breach of any provision of this Agreement, and does not cure such breach within sixty (60) days after delivery of written notice from Board.
“Breach” includes, but is not limited to, provisions of this Agreement for which Licensee is on specific notice that a specific action, or failure to perform a specific action, constitutes a breach, including but not limited to
Section 6.1 (“Royalty Reports”), Section 8.2 (“Default in Payment”), Section 8.1 (“Future Patent Expense Payment Plan), and Section 11.4 (“Board’s Prosecution Rights”).

 Furthermore, if, in any one twelve (12) month period, Board or University delivers notice to Licensee of
three (3) or more breaches of this Agreement, even in the event that Licensee cures such breaches in the allowed period, Board may immediately terminate this Agreement upon delivery of notice of termination to Licensee. 

 

	8.4	Other Conditions of Termination 

 This Agreement will earlier terminate: 
  

	 	a.	Immediately without the necessity of any action being taken by Board or Licensee, if Licensee becomes bankrupt or Insolvent and/or if the business of Licensee is placed
in the hands of a receiver, assignee, or trustee, whether by voluntary act of Licensee or otherwise; or 

  

	 	b.	at any time by mutual written agreement between Licensee and Board and subject to any terms herein which survive termination. 

 

	8.5	Survival 

 If this
Agreement is terminated for any reason: 
  

	 	a.	except in the case of termination under Section 8.1 (“Termination at End of Term”), Licensee will immediately cease use of confidential Licensed Subject
Matter; 

  

	 	b.	Licensee will comply with the provisions of Section 9.4 (“Copies”); 

 

	 	c.	nothing in this Agreement will be construed to release either party from any obligation that matured prior to the effective date of termination; and

  

	 	d.	after the effective date of termination, Licensee may sell all Licensed Product(s) and parts thereof that it has on hand at the effective date of termination; provided,
however, that Licensee’s royalty obligations will continue until all Licensed Product(s) have been sold. 

The provisions of Sections 9 (“Confidentiality”), 101 (“Infringement and Litigation”), 12 (“Representations and
Disclaimers”), 14 (“Limit of Liability”), 15 (“Indemnification”), 16 (“Insurance”), 19 (“Use of Name”), and 201 (“General Provisions”) will survive any termination or expiration of this
Agreement. 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 12 of 30

	9.	Confidentiality 

  

	9.1	Protection and Marking 

Any disclosure of Confidential Information is made in the strictest confidence. The Licensee and University will make all reasonable
efforts to ensure the protection, confidentiality and security of any Confidential Information in its possession, such efforts to be no less than the degree of care employed by the Licensee or University to preserve and safeguard its own
confidential information. Confidential Information will be transmitted in writing and clearly marked “Confidential”, “Proprietary” or similarly, or if disclosed orally will be reduced to writing by the University, clearly marked
“Confidential”, “Proprietary” or similarly, and transmitted to the Licensee in accordance with Section 19 (“Notices”) within thirty (30) days of oral disclosure. 

 

	9.2	Non-Disclosure 

 Each
party to this Agreement may disclose the Confidential Information to its own employees in connection with the rights granted under this Agreement; provided, however, that such employees will have agreed to be bound by the terms of this Agreement or
have entered into an agreement of similar scope and obligations to protect the confidential information of such party or the confidential information of third parties in such party’s possession. In no event will either party disclose
Confidential Information to third parties without the written consent of the other party; provided, however, that Licensee may disclose Confidential Information to its consultants, other non-employees retained because of their standing and expertise
in the area, and customers or potential customers; provided, that such consultant, non-employee, or customers or potential customers have executed a written non-disclosure and non-use agreement containing terms and conditions approved in writing by
University. A copy of any such executed agreement will be provided to University in the manner set forth in Section 20 (“Notices”). 
  

	9.3	Non-Use 

 Licensee or
University will not use any Confidential Information for any reason other than in connection with practice or exercise of the rights granted under this Agreement without the prior written consent of the Board or University. 

 

	9.4	Copies 

 The Licensee and
University agrees not to copy or record any Confidential Information except as reasonably necessary for University or Licensee to practice or exercise the rights granted under this Agreement. Within five (5) days after the termination of this
Agreement, upon request of the University or Licensee, Licensee or University will deliver to the other all copies or records of Confidential Information in its possession or control, or will certify in writing to the other that the Confidential
Information has been destroyed. 
  

	9.5	Continuing Obligations 

Subject to the exceptions listed below, the Licensee’s and University’s obligations under this Agreement will survive
termination of this Agreement and will continue for a period of five (5) years. 
 Confidential Information will not include
any information which: 
  

	 	a.	can be demonstrated to have been in the public domain as of the Effective Date of this Agreement or comes into the public domain during the term of this Agreement
through no fault of the party who received the other party’s Confidential Information; 

  

	 	b.	can be demonstrated, from written records, to have been known to one of the Parties to this Agreement prior to the Effective Date of this Agreement and was not
acquired, directly or indirectly, from the Board or University or from a third party under a continuing obligation of confidentiality or limited use; 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 13 of 30

	 	c.	can be demonstrated to have been rightfully received by one of the Parties from a third party who did not require the Parties to hold it in confidence or limit its use
and who did not acquire it, directly or indirectly, from the Parties a continuing obligation of confidentiality; or 

  

	 	d.	is required to be disclosed by a court of competent jurisdiction after giving maximum practical notice to the Licensee or Board and University.

  

	9.6	Degree of Care and Survival of Obligations 

 Licensee’s and University’s obligation of confidence hereunder will be fulfilled by using at least the same degree of care with the Confidential Information as Licensee uses to protect its own
confidential information. 
  

	9.7	Publication by University 

University will submit its manuscript for any proposed publication of research related to Licensed Subject Matter to Licensee at least
thirty (30) days before publication, and Licensee will have the right to review and comment upon the publication in order to protect Licensee’s confidential information. Upon Licensee’s request, publication will be delayed up to sixty
(60) additional days to enable Licensee to secure adequate intellectual property protection of Licensee’s property that would be affected by the publication. 
  

	9.8	Copyright Notice 

 The
placement of a copyright notice on any Confidential Information will not be construed to mean that such information has been published and will not release Licensee from its obligation of confidentiality hereunder. 

 

	10.	Infringement and Litigation 

  

	10.1	Notification 

 University
and Licensee are responsible for notifying each other promptly of any infringement of Licensed Patents or any misappropriation of Confidential Information or Licensed Technology that may come to their attention. University and Licensee will consult
one another in a timely manner concerning any appropriate response thereto. 
  

	10.2	Licensee Prosecution Rights 

 Licensee will have the right, but not the obligation to prosecute such infringement or misappropriation at its own expense. Licensee will not settle or compromise any such suit in a manner that imposes
any obligations or restrictions on Board or University or grants any rights to Licensed Patents or Licensed Technology, without Board’s prior written consent. At the time of filing any infringement enforcement action, Board and Licensee will
determine how any damages awarded will be distributed between Board and Licensee; using as a guide and provided that in no event will Board’s distribution be less than an amount that would have been due Board based upon Section 4.5
(“Sublicensee Fees”) as if the litigation recovery had been a Sublicensee Fee, or if no Sublicensee Fee is due to Board, subject first to any payments that would have been due University based upon Section 4.1 (“Running
Royalty”) as if the litigation recovery had been from a Sale. 
  

	10.3	Board’s Right to Intervene 

 If Licensee shall fail, within one hundred twenty (120) days after receiving notice from Board of a potential infringement, or providing Board with notice of such infringement, to either
(a) terminate such infringement or (b) institute an action to prevent continuation thereof including, but not limited to, cross-licensing agreements, marketing agreements, licensing agreements, and etc.; and, thereafter to prosecute such
action diligently, or if Licensee notifies Board that it does not plan to terminate the infringement or institute such action, then Board shall have the right to do so at its own expense. Licensee’s prosecution rights under Section 10.2
(“Licensee Prosecution Rights”) will be subject to the continuing right of Board or University to intervene at Board’s or University’s own expense and join Licensee in any claim or suit for infringement or misappropriation of
Licensed Patents or Licensed Technology. Any consideration 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 14 of 30

 
received in settlement of any claim or suit will be shared between University and Licensee in a proportionate amount to be determined at the time of intervention, based on royalties that would
have been due if no infringement had occurred. 
  

	10.4	Board’s Prosecution Rights 

 If Licensee fails to prosecute or remedy through agreement or settlement such infringement or misappropriation within six (6) months of notice of infringement or misappropriation, Board or University
will have the right, but not the obligation, to prosecute such infringement or misappropriation at its own expense. Board will have the additional right, if Licensee fails to prosecute or remedy through agreement or settlement such infringement or
misappropriation within said six (6) months, to (i) terminate any and all license rights granted to Licensee with respect to the Licensed Subject Matter being infringed or misappropriated, or (ii) convert the license rights granted to
Licensee from exclusive to non-exclusive with respect to the Licensed Subject Matter being infringed or misappropriated. In the event Board exercises either of these options, Board may grant non-exclusive license rights to the infringer for said
Licensed Subject Matter and/or any field(s) of use with Board or University retaining [**]% of all consideration for said license grant. 
  

	10.5	Cooperation between Board, University, and Licensee 

 In any action to enforce any of the Licensed Patents or Licensed Technology, either party to this Agreement, at the request and expense of the other party, will cooperate to the fullest extent reasonably
possible. This provision will not be construed to require either party to undertake any activities, including legal discovery, at the request of any third party except as may be required by lawful process of a court of competent jurisdiction.

  

	11.	Export Compliance 

Licensee understands that the Arms Export Control Act (AECA), including its implementing International Traffic In Arms Regulations (ITAR,)
and the Export Administration Act (EAA), including its Export Administration Regulations (EAR), are some (but not all) of the laws and regulations that comprise the U.S. export laws and regulations. Licensee further understands that the U.S. export
laws and regulations include (but are not limited to): (1) ITAR and EAR product/service/data-specific requirements; (2) ITAR and EAR ultimate destination-specific requirements; (3) ITAR and EAR end user-specific requirements;
(4) ITAR and EAR end use- specific requirements; (5) Foreign Corrupt Practices Act; and (6) anti-boycott laws and regulations. Licensee will comply with all then-current applicable export laws and regulations of the U.S. Government
(and other applicable U.S. laws and regulations) pertaining to the Licensed Technology (including any associated products, items, articles, computer software, media, services, technical data, and other information). Licensee certifies that it will
not, directly or indirectly, export (including any deemed export), nor re-export (including any deemed re-export) the Licensed Technology (including any associated products, items, articles, computer software, media, services, 

 

	**	Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment
Request. 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 15 of 30

 technical data, and other information) in violation of U.S. export laws and regulations or
other applicable U.S. laws and regulations. Licensee will include an appropriate provision in its agreements with its authorized Sublicensees to assure that these parties comply with all then-current applicable U.S. export laws and regulations and
other applicable U.S. laws and regulations 
  

	12.	Representations and Disclaimers 

  

	12.1	Board Representation 

Except for the rights, if any, of the Government of the United States, as set forth below, Board represents its belief that (i) it is
the owner of the entire right, title, and interest in and to Licensed Subject Matter, (ii) it has the sole right to grant licenses to the Licensed Subject Matter, and (iii) it has not knowingly granted licenses to the Licensed Subject
Matter to any other entity that would restrict rights granted to Licensee except as stated herein. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, BOARD MAKES NO REPRESENTATIONS, WARRANTIES OR CONDITIONS, EXPRESS OR IMPLIED. 

 

	12.2	Government Rights 

Licensee understands that the Licensed Subject Matter may have been developed under a funding agreement with the Government of the United
States of America and, if so, that the Government may have certain rights relative thereto. This Agreement is explicitly made subject to the Government’s rights under any agreement and any applicable law or regulation. If there is a conflict
between an agreement, applicable law or regulation and this Agreement, the terms of the Government agreement, applicable law or regulation will prevail. 
  

	12.3	Board Disclaimers 

Licensee understands and acknowledges that (i) Board, by this Agreement, makes no representation as to the operability or fitness for
any use, safety, efficacy, ability to obtain regulatory approval, patentability, and/or breadth of the Licensed Subject Matter or as to whether there are any patents now held, or which will be held, by others or by Board in the Licensed Field, or as
to whether the inventions contained in Licensed Patents do not infringe any other patents now held or that will be held by others or by Board, or as to whether Licensed Technology has been misappropriated; (ii) nothing in this Agreement will be
construed as conferring by implication, estoppel or otherwise any license or rights to any patents or technology of Board other than the Licensed Subject Matter, whether such patents are dominant or subordinate to the Licensed Patents; and
(iii) Board has no obligation to furnish to Licensee any technology or technological information other than the Licensed Technology. 
  

	12.4	Licensee Representations 

By execution of this Agreement, Licensee acknowledges, covenants and agrees that it has not been induced in any way by Board, System,
University or its employees to enter into this Agreement, and further warrants and represents that (i) it has conducted sufficient due diligence with respect to all items and issues pertaining to this Section 12 (“Representations and
Disclaimers”) and all other matters pertaining to this Agreement; and (ii) Licensee has adequate knowledge and expertise, or has utilized knowledgeable and expert consultants, to adequately conduct the due diligence, and agrees to
accept all risks inherent herein. Licensee represents that it is a duly organized, validly existing C- Corporation in good standing under the laws of Delaware and has all necessary corporate power and authority to execute, deliver and perform its
obligations hereunder. 
  

	13.	Limit of Liability 

 IN NO EVENT WILL
BOARD OR UNIVERSITY BE LIABLE FOR ANY DIRECT, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR EXPECTED SAVINGS OR OTHER ECONOMIC LOSSES, OR FOR INJURY TO PERSONS OR PROPERTY) ARISING OUT OF
OR IN CONNECTION WITH THIS AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER BOARD OR UNIVERSITY 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 16 of 30

 
KNOWS OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES. BOARD’S AND UNIVERSITY’S AGGREGATE LIABILITY FOR ALL DAMAGES OF ANY KIND RELATING TO THIS AGREEMENT OR ITS SUBJECT MATTER
SHALL NOT EXCEED THE AMOUNTS PAID BY LICENSEE TO UNIVERSITY UNDER THIS AGREEMENT DURING THE ONE YEAR PERIOD PRECEDING THE DATE OF THE EVENT WHICH GAVE RISE TO THE LIABILITY. THE FOREGOING EXCLUSIONS AND LIMITATIONS WILL APPLY TO ALL CLAIMS AND
ACTIONS OF ANY KIND, WHETHER BASED ON CONTRACT, TORT (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE), OR ANY OTHER GROUNDS. 
  

	14.	Indemnification 

 Licensee agrees to hold
harmless and indemnify Board, System, University, its Regents, officers, employees and agents (the “Indemnitees”) from and against any claims, demands, or causes of action whatsoever, including without limitation those arising on account
of any injury or death of persons or damage to property caused by, or arising out of, or resulting from, the exercise or practice of the license granted hereunder by Licensee, Affiliates, Sublicensees or their officers, employees, agents or
representatives. 
  

	15.	Insurance 

  

	15.1	Insurance Requirements 

Beginning at the time any Licensed Subject Matter is being distributed or Sold (including for the purpose of obtaining any required
regulatory approvals) by Licensee or a Sublicensee, Licensee will, at its sole cost and expense, procure and maintain commercial general liability insurance issued by an insurance carrier with an A.M. Best rating of “A” or better in
amounts not less than $1,000,000 per incident and $1,000,000 annual aggregate. Licensee will use reasonable efforts to have the Indemnities named as additional insureds. All rights of subrogation will be waived against Board, University and its
insurers. Such commercial general liability insurance will provide (i) product liability coverage; (ii) broad form contractual liability coverage for Licensee’s indemnification under this Agreement; and (iii) coverage for
litigation costs. The specified minimum insurance amounts will not constitute a limitation on Licensee’s obligation to indemnify the Indemnitees under this Agreement. 

 

	15.2	Evidence of Insurance and Notice of Changes 

 Licensee will provide University with written evidence of such insurance upon request of University. Licensee will provide University with written notice of at least thirty (30) days prior to the
cancellation, non-renewal or material change in such insurance. 
  

	15.3	Continuing Insurance Obligations 

 Licensee will maintain such commercial general liability insurance beyond the expiration or termination of this Agreement during (i) the period that any Licensed Subject Matter developed pursuant to
this Agreement is being commercially distributed or Sold by Licensee, any Affiliate, or any Sublicensee or agent of Licensee; and (ii) for five (5) years after such period. 

 

	15.4	Additional Insurance 

Board reserves the right to request additional policies of insurance where appropriate and reasonable in light of Licensee’s business
operations and availability of coverage. 
  

	16.	Assignment 

 This Agreement may be
assigned by Licensee without the prior written consent of Board. In the event this Agreement is so assigned, or in the event of any transfer by operation of law (e.g., a merger or reorganization or consolidation of Licensee), Licensee will pay a
non-refundable fee of [**] ($[**]) if the total transaction value is more than [**] ($[**]). 
  

	**	Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment
Request. 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 17 of 30

	17.	Governmental Markings 

  

	17.1	Patent Marking 

 Licensee
must permanently and legibly mark all products, where feasible, and documentation manufactured or Sold under this Agreement with patent notice appropriate under Title 35, United States Code. 

 

	17.2	Governmental Approvals and Marketing of Licensed Products 

 Licensee will be responsible for obtaining all necessary governmental approvals for the development, production, distribution, sale, and use of any Licensed Subject Matter, at Licensee’s expense,
including, without limitation, any safety studies. Licensee will have sole responsibility for any warning labels, packaging and instructions as to the use, and for the quality control for any Licensed Subject Matter. 

 

	17.3	Foreign Registration 

Licensee agrees to register this Agreement with any foreign governmental agency that requires such registration and Licensee will pay all
costs and legal fees in connection with such registration. Licensee will assure that all foreign laws affecting this Agreement or the sale of Licensed Subject Matter are fully satisfied. 

 

	18.	Use of Name 

  

	18.1	By Licensee 

 Licensee may
use the name “The University of Texas at Austin” in factually based materials related to the Licensed Subject Matter and the business of the Licensee; provided, however, that Licensee may not use the name of System, Board or University in
connection with any name, brand or trademark related to Licensed Subject Matter. For example, Licensee may include a statement in promotional materials that refers to the fact that a product or service is based on technology developed at The
University of Texas at Austin; Licensee may not include The University of Texas at Austin in a product or service name. 
  

	18.2	By Board or University 

Board or University may use Licensee’s name in connection with Board or University publicity related to University intellectual
property and commercialization achievements. 
  

	19.	Notices 

 Any notice or other
communication of the parties required or permitted to be given or made under this Agreement will be in writing and be deemed effective when sent to the address set forth below (or as changed by written notice pursuant to this Section 19) by
certified or registered mail, postage prepaid, return receipt requested or by internationally recognized overnight courier. Notices required under this Agreement may not be delivered via E-mail. 

In the case of Board to: 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 18 of 30

							
		  	Office of Technology Commercialization	  		  	
		  	The University of Texas at Austin	  		  	
		  	3925 West Braker Lane, Suite 1.9A	  		  	
		  	MCC Building, Mail Code: R3500	  		  	
		  	Austin, Texas 78759	  		  	
		  	Attn: Contract Manager	  		  	
		  	Fax: (512) 475-6894	  		  	
		  	Phone: (512) 471-2995	  		  	

 or in the case of Licensee to: 
  

							
		  	mailto:	  		  	
		  	AxoGen Corporation	  		  	
		  	PO Box 357787	  		  	
		  	Gainesville, FL 32635-7787	  		  	

  

	20.	General Provisions 

  

	20.1	Binding Effect 

 This
Agreement is binding upon the parties hereto, their respective executors, administrators, heirs, assigns, and successors in interest. 
  

	20.2	Construction of Agreement 

Headings are included for convenience only and will not be used to construe this Agreement. The parties acknowledge and agree that both
parties substantially participated in negotiating the provisions of this Agreement; therefore, both parties agree that this Agreement shall not be construed more favorably toward one party than the other party, regardless of which party primarily
drafted the Agreement. 
  

	20.3	Counterparts 

 This
Agreement may be executed in multiple counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument. 

 

	20.4	Enforcement 

 In the event
either party commences any proceeding against the other party with respect to this Agreement, the prevailing party (as determined by the authority before whom such proceeding is commenced) will be entitled to recover reasonable attorneys’ fees
and costs as may be incurred in connection therewith in addition to any such other relief as may be granted. 
  

	20.5	Compliance with Laws 

Licensee will comply with all applicable federal, state and local laws and regulations, including, without limitation, all export laws and
regulations. 
  

	20.6	E-mails 

 The parties
acknowledge that they may correspond or convey documentation via Internet e-mail, but that no agreement between the parties will be entered into or notices provided via e-mail communications. 

 

	20.7	Governing Law 

 This
Agreement will be construed and enforced in accordance with laws of the United States of America and the State of Texas, without regard to choice of law and conflicts of law principles. 

 

	20.8	Modification 

 Any
modification of this Agreement will be effective only if it is in writing and signed by duly authorized representatives of both parties. 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 19 of 30

	20.9	Severability 

 If any part
of this Agreement is for any reason found to be unenforceable, invalid, or void, all other parts will remain enforceable. 
  

	20.10	Survival 

 The survival
provisions of this Agreement are set forth in Section 8 (“Term and Termination”). 
  

	20.11	Third Party Beneficiaries 

Nothing in this Agreement, express or implied, is intended to confer any benefits, rights or remedies on any Entity, other than the
parties and their successors and permitted assigns. 
  

	20.12	Waiver 

 Neither party
will be deemed to have waived any of its rights under this Agreement unless the waiver is in writing and signed by such party. 
  

	20.13	Entire Agreement 

 This
Agreement constitutes the entire Agreement between the parties regarding the subject matter hereof, and supersedes all prior written or verbal agreements, representations and understandings relative to such matters. 

IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives to execute this Agreement. 

 

									
	ON BEHALF OF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM	 		 	LICENSEE
					
	By	 	     /s/ Juan M. Sanchez
	 		 	By	 	     /s/ Jamie M. Grooms

	Juan M. Sanchez, Ph.D.	 		 		 	
	Vice President for Research	 		 		 	
	The University of Texas at Austin	 		 		 	
					
	Date	 	     July 22, 2005
	 		 	Date	 	     August 3, 2005

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 20 of 30

 EXHIBIT A: LICENSED PATENTS 

[**] 
  

 

	**	Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment
Request. 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 21 of 30

 EXHIBIT B: PROGRESS PLAN AND COMMERCIALIZATION REPORT 

INSTRUCTIONS TO EXHIBIT B 
 PROGRESS REPORT AND COMMERCIALIZATION PLAN 
  

	I.	General 

 Licensee shall annually submit a
progress report (“Report”) and commercialization plan (“Plan”), (collectively, the “Submissions”) in the format outlined below to University beginning on the first anniversary of the Effective Date of this Agreement, as
outlined in Section 2.4. The information provided in the Submissions is subject to audit by The University of Texas. The University of Texas may terminate its License with Licensee if any information provided in the Submissions is intentionally
and materially misreported. 
  

	A.	Purpose 

 The information provided by
Licensee in the Submissions is required by the License Agreement and also is critical to the technology commercialization process. By providing the information requested in this document, you can help us: 

 

	 	•	 	 track the progress and document the successes of the commercialization effort around the Licensed Subject Matter, 

 

	 	•	 	 promote research, development and commercialization and 

 

	 	•	 	 improve the technology licensing process at the University. 

 Licensee should provide as much information as is necessary to clearly demonstrate the commercialization of the Licensed Subject Matter. Failure to demonstrate commercialization of Licensed Subject Matter
could result in termination of the License Agreement pursuant to Section 4.6 of License Agreement. 
  

	B.	Submissions Format 

 The following format
must be followed for each required submission. Submissions that deviate substantially from these guidelines or that omit substantial information will not be considered submitted nor acceptable for the purpose of determining Licensee’s
compliance with License Agreement and its reporting requirements; provided, however, that unsatisfactory submissions shall be returned to Licensee with sufficient detail regarding the deviations which make the submission non-conforming so as to
allow Licensee to resubmit a conforming submission prior to the declaration by Licensor of a Licensee default under the License Agreement. 
  

	1.	 Page Limitations. Page and paragraph limitations for the different parts of the Submissions are stipulated in the requirements section (below)
and should be adhered to. If additional explanation is required, please attach typed explanation on 8
 1/2 x 11 inch pages using 1 inch margins. All
additional pages should clearly indicate in the heading, the section and subsection (e.g., II.a.1, III.B, etc.) to which they relate and must follow all other Submissions format requirements. 

 

	2.	Tables Provided in Appendix C. In order to simplify the Submissions review process, Excel tables are provided for Licensee to complete. Licensee must complete
each table provided or indicate Not Applicable (“N/A”). (Note: Tables in Excel format may be modified to add additional rows or widen columns as necessary. For example, in Section II.B.4., a Licensed Product may have more than one current
commercialization partner and thus another column should be added, however, if the Licensed Product does not have any current commercialization partners, no columns should be deleted. Simply indicate, “None”.) 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 22 of 30

	C.	General Instructions 

  

	1.	Period 

 The Report must cover a one year
period, (“Report Period”) beginning on the anniversary of the Effective Date and ending on the day before the following anniversary of the Effective Date. 
 The Plan must cover a minimum of a three year period, (“Plan Period”) beginning on the anniversary of the Effective Date and ending on the day before the second following anniversary of the
Effective Date. 
  

	2.	Due Date 

 Paper copies of the completed
Submissions are due on the anniversary of the Effective Date, (“Due Date”), and each anniversary thereafter. Licensee is responsible for ensuring the Submissions are submitted by the Due Date. The Submissions will be deemed submitted on
time if post-marked or received on or before the Due Date. It is recommended that Licensee send the completed Submissions via certified mail-return receipt requested (or via overnight delivery with signature requested). Submissions not submitted by
the Due Date will be considered late and may result in breach and/or termination of License Agreement. 
 All Submissions should be sent to the
following address: 
 Office of Technology Commercialization 

The University of Texas at Austin 
 3925 W. Braker Lane 
 MCC Building Suite 1.9A 

Austin, Texas 78759 
 Attention: Contract Manager 
  

	II.	Progress Report Requirements 

 Indicate
all achievements and milestones made during the Report Period as outlined below including the completion of the tables in Appendix C. Attach all requested documentation and attach additional pages as necessary to the back of Appendix C. 

Note: For each requirement, please include the efforts of each Sublicensee individually. 

 

	A.	Product Development 

  

	1.	Development Activity 

 a) Dates of
completion of a first commercial prototype for each Licensed Product. 
 b) Dates of completion of a manufacturing facility for each Licensed
Product (if different). If a manufacturing facility is currently available, please indicate N/A. 
 c) Date of first commercial Sale of each
Licensed Product. 
 d) Working capital invested during the Report Period (e.g., amount of non-contingent, operating capital to proceed with the
exploration and development of the Licensed Subject Matter) for each Licensed Product for each stage completed and in progress. 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 23 of 30

	2.	Regulatory Approval Process Activity (if applicable, e.g. FDA approvals) 

 a) List stages of the approval process completed during the Report Period with corresponding completion dates for each Licensed Product requiring regulatory approval. 

 

	3.	Intellectual Property Acquisition Activity 

 a) List any intellectual property (patent #s/patent app#) including inventor names that the company has licensed or developed in order to commercialize the Licensed Subject Matter. 

 

	4.	Other Activity 

 a) List and describe any
other achievements made during the Report Period with respect to Licensed Subject Matter or Licensed Products including relevant test result data and success metrics. Attach additional pages if necessary. 

 

	B.	Business Development 

  

	1.	Marketing and Sales Activity 

 a) Denote
marketing Plan milestones achieved during the Report Period and other sales/marketing achievements. 
 b) List Sales of each Licensed Product
containing Licensed Subject Matter during the Report Period. 
 c) List Licensed Fields that Licensee has or is in the process of
commercializing, during the Report Period. 
 d) List and describe all current partnerships relevant to the commercialization of Licensed
Subject Matter existing or formed during Report Period. 
 e) Provide any other marketing or sales accomplishments and materials attributable to
Report Period (including press releases, product brochures, etc...). 
  

	2.	Corporate Development Activity 

 a) List
any funding events that occurred during report period (with updated Capitalization Table if Board, System or University received equity by the License Agreement). 
 b) Provide any other Corporate Development Activity during Report Period (including key hires or organizational changes, and acquisition, divestiture or other large transaction information). 

 

	III.	Commercialization Plan Requirements 

Indicate all commercialization plans, projections and timelines for Licensed Subject Matter applicable to the Plan Period including the completion of the
tables in Appendix C. Attach all requested documentation and attach additional pages as necessary to the back of Appendix C. 
 Note: For each
requirement, please include the efforts of each Sublicensee individually. 
  

	A.	Product Development 

 Provide an updated
product development plan outlining specific product development milestones and dates by which they will be achieved. Use the tables provided in Appendix C and be sure to reflect any changes and updates to the Plan from the previous Plan. 

If the Company is also attaching a product development plan prepared for its own use, please denote all relevant sections of the plan which detail
Licensed Products. 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 24 of 30

 For all changes to the Plan from a prior Plan, please detail reasons for such changes. Attach additional
pages, if necessary. 
  

	B.	Regulatory Approval (if applicable e.g. FDA approval) 

 Provide an updated timeline with milestones for each stage of the required government regulatory approval process(es). Please use the tables provided in Appendix C and be sure to reflect any changes and
updates to the Plan from the previous Plan. 
 For all changes to the timeline from a prior Plan, please detail reasons for such changes. Attach
additional pages, if necessary. 
  

	C.	Business Development 

 Provide an updated
summary of Licensee’s plans as to projected market(s), sales forecasts, manufacturing, operations and corporate developments. 
 The
updated marketing plan shall include as a minimum, the following information: Analysis of target market(s) for each Licensed Product, including target market size, anticipated partnerships, estimated market share and product differentiation strategy
(approximately 2-3 paragraphs). 
 If the Company is also attaching a marketing plan prepared for its own use, please denote all relevant
sections of the plan which detail products and initiatives relating to Licensed Subject Matter. 
 For all changes to the Plan from a prior
plan, please detail reasons for such changes. Attach additional pages, if necessary. 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 25 of 30

 FORM FOR PROGRESS REPORT AND COMMERCIALIZATION PLAN 

Licensee: 
 Name of Licensed Subject Matter:

 Plan Period: 
 List of Licensed
Products and Corresponding Fields of Use: 
 Company Representatives 
 Prepared By: 
 Approved By: 

 

	I.	Progress Report Requirements 

 Provide all
required information and complete all relevant tables below or indicate “N/A” for not applicable 
  

	A.	Product Development 

  

	1.	Provide Development Activity into tables provided below: 

  

									
	 Licensed product
	  	a. Date Prototype
Completion	  	b. Date manufacturing
facility available	  	c. Date of first
commercial sale	  	d. Working capital
invested
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	

  

	2.	Provide Regulatory Approval Process Activity, if applicable, into tables provided below: 

Licensed
Product                                        
 
 {Regulatory Agency} 
  

			
	 Approval Stage or Phase
	  	Completion Date
		  	
		  	
		  	

 Licensed
Product                                        
 
 {Regulatory Agency} 
  

			
	 Approval Stage or Phase
	  	Completion Date
		  	
		  	
		  	

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 26 of 30

	3.	Provide Intellectual Property Acquisition Activity into the table provided below: 

 

					
	 Patent no./Patent app. no.
	  	Inventor name(s)	  	Title(s)
		  		  	
		  		  	
		  		  	

  

	4.	Provide Other Activity below and attached as necessary: 

  

	B.	Business Development 

  

	1.	Provide Marketing and Sales Activity in the tables and space below: 

  

	 	a)	Marketing Plan Milestones Achieved 

  

			
	 Marketing Plan Milestone
	  	Date Achieved
		  	
		  	
		  	

  

	 	b)	Sales of each Licensed Product 

  

			
	 Licensed product name
	  	Sales
		  	
		  	
		  	

  

	 	c)	Fields of Use pursued 

  

			
	 Fields of use
	  	Yes/No
		  	
		  	
		  	

  

	 	d)	Commercialization Partnerships 

  

					
	 Licensed product
	  	Current or Anticipated	  	Nature of Relationship
		  		  	
		  		  	
		  		  	

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 27 of 30

	 	e)	Provide other sales or marketing activity below and attached as necessary (including press releases and marketing collateral): 

 

	2.	Provide Corporate Development Activity in the tables and space below: 

  

	 	a)	Funding Events (attach updated Capitalization Table if applicable) 

  

					
	 Date
	  	Investors	  	Funding Amount
		  		  	
		  		  	
		  		  	

  

	 	b)	Provide other corporate development activity below and attached as necessary. 

 

	II.	Commercialization Plan Requirements 

Provide all required information and complete all relevant tables below or indicate “N/A” for not applicable. 

 

	A.	Product Development. 

 Provide 2-3
paragraphs describing the product development plan for each Licensed Product in development during Plan Period. 
  

									
	 Licensed product
	  	Date of Prototype
Completion	  	Date manufacturing
facility available	  	Date of first commercial
sale	  	Anticipated Capital
Investment
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	

  

	B.	Regulatory Approval. 

 Provide an updated
projection of milestones with regard to Regulatory Approvals. If this Plan represents a change from the previous Plan, please provide the reasons: 
  

									
	 {Regulatory Agency
 Stage or Phase}
	  	Key personnel assigned	  	Estimated start time	  	Estimated end time	  	Estimated cost to
complete
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 28 of 30

	C.	Business Development 

 Provide 2-3
paragraphs describing the business development plan for each Licensed Product to be marketed during Plan Period.: 
 Please enter changes in the
following table: 
  

													
	 Licensed
 product
	  	Year of
expected first
sale	  	Revenue forecast
	  	  	Year 1	  	Year 2	  	Year 3	  	Year 4	  	Year 5
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	

 Please enter changes in the following table: 

 

					
	 Licensed product
	  	Current partner	  	Anticipated partner
		  		  	
		  		  	
		  		  	

 Please enter changes in the following table: 

 

			
	 Fields of use
	  	Yes/No
		  	
		  	
		  	

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 29 of 30

 EXHIBIT C: FORM OF SALES AND ROYALTY REPORT 

INSTRUCTIONS TO EXHIBIT C 
  

									
	 Licensee:
	  		  	UT Agreement No:                    
        	  	
			
	Period Covered:	  	From:         /         /        	  	through:         /        
/        
				
	Prepared by:	  	  

(company representative)
	  	Date:	  	
				
	Approved by:	  	  

(company representative)
	  	Date:	  	

 If license covers several major product lines, please prepare a separate report for each line. Then combine all product
lines into a summary report. 
  

									
	 Report Type:
	  	 ̈	 	  	  	Single Product or Process Line
Report:                                        
                                         
                   	  	
		  				  	(product name)	  	
				
		  	 ̈	 	  	  	Multiproduct Summary Report, page 1 of              pages	  	
				
	 Other Compensation:
	  	 ̈	 	  	  	Annual payments, milestones, other fees &
compensation:                                       
                         	  	
		  				  	    Amount
due:                                    	  	
				
		  	 ̈	 	  	  	No Compensation or Royalty Due this Period	  	
		  				  	    Reason
why:                                        
                                         
                                         
                      	  	

  

															
	 Country
	  	 Quantity
Produced
	  	Quantity
Sold	  	Gross
Sales ($)	  	*Net
Sales ($)	  	Royalty
Rate	  	Conversion
Rate (if
applies)	  	Royalty Due
This Period
								
	USA	  		  		  		  		  		  		  	
								
	Canada	  		  		  		  		  		  		  	
								
	Japan	  		  		  		  		  		  		  	
								
	Other:	  		  		  		  		  		  		  	
								
	Sublicensee # 1	  		  		  		  		  		  		  	
								
	  
	  		  		  		  		  		  		  	
	Name	  		  		  		  		  		  		  	
								
	Sublicensee # 2	  		  		  		  		  		  		  	
								
	  
	  		  		  		  		  		  		  	
	name	  		  		  		  		  		  		  	
	TOTAL:	  		  		  		  		  		  		  	

  

	*	To calculate Net Sales, use the following space to list separately the specific types of allowed deductions under our agreement and the corresponding amount

  
  

Then calculate the final Net Sales amount by subtracting these deductions from Gross Sales, and note in the column above 

  

							
	The University of Texas at Austin	  		  	

			
	
Licensee:                      
                                         
              
	  	
	
UTA No.:                      
                                         
             
	  	Page 30 of 30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]